About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

LDCT May Help Detect Twice As Many Lung Cancers As X-Rays

by Dr. Enozia Vakil on May 26, 2013 at 9:53 PM
Font : A-A+

LDCT May Help Detect Twice As Many Lung Cancers As X-Rays

New publication reveals that physicians have a lot more information to share with their patients regarding the benefits and risks of LDCT lung cancer screening. "For a cancer screening to work, it's important to verify that it can in fact discover cancers early.

The analysis of NLST participants initial annual screening examination provides evidence that the number of early-stage cancers detected in the trial's CT arm were significantly greater than the number detected in the chest X-ray arm," says Timothy Church, Ph.D., a biostatistician and professor in the School of Public Health at the University of Minnesota who has been involved with the NLST's design, implementation and analysis. Church also points out that a reduction in mortality is the ultimate indicator of a successful cancer screening strategy. The NLST is a large-scale, longitudinal clinical trial that randomized over 53,400 study participants equally into either the LDCT or standard CXR arm to evaluate whether lung cancer screening saves lives. Published results (NEJM; 2011) reported a 20 percent reduction in lung cancer deaths among study participants (all at high risk for the disease) screened with LDCT versus those screened with CXR.

Advertisement

The authors report that the NLST initial-screening results are reflective of other large trials with regard to positive LDCT versus CXR results, with more positive screening exams [7191 vs. 2387, respectively], more diagnostic procedures [6369 vs. 2176, respectively], more biopsies and other invasive procedures [297 vs. 121, respectively], and more lung cancers seen in the LDCT arm than in the CXR arm during the first screening round of NLST [292 vs. 190, respectively]. Although these results were generally anticipated, a key reason to publish the data was to document the exact differences between the two arms. "Although we did see that CT resulted in referring more patients for additional testing, the question comes down to whether the 20 percent reduction in mortality is worth the additional morbidity introduced by screening high-risk patients," says Church. He notes that although there were more follow-up procedures in the LDCT versus the CXR arm, it was encouraging to confirm that the number of individuals who actually had a more invasive follow-up procedure was quite small.

Another encouraging result reported is the high rate of compliance in performing the LDCT examination as specified in the research protocol across the 33 imaging facilities that carried out the study. "The sites complied with the low-dose CT imaging protocol specifications in 98.5 percent of all studies performed, which is outstanding considering the many thousands of scans performed," states Denise R. Aberle, M.D., the national principal investigator for NLST ACRIN and site co-principal investigator for the UCLA NLST team. Aberle, a member of the UCLA Jonsson Comprehensive Cancer Center, professor of Radiology and Bioengineering and vice chair for Research in Radiology at UCLA, also emphasizes that the first-screen result strongly suggests that CT lung cancer screening programs with radiologists who possess similar expertise and interpret similar numbers of CT cases that are obtained on scanners of the same caliber or better as those required for the NLST are likely to have results similar to those reported in the paper.
Advertisement

"What we''ve learned from the analysis of the first-screen results provides clinicians additional facts to discuss with patients who share similar characteristics as the NLST participants (current or former heavy smokers over the age of 55)", says Church. "The results also caution against making blanket lung cancer screening recommendations, because each person's trade-off between the risk of having an unnecessary procedure and the fear of dying of lung cancer is uniquely individual."

"Today's publication represents the type of immensely important data NLST will continue to provide about lung cancer screening in the United States," says Mitchell J. Schnall, M.D., Ph.D., ACRIN Network Chair, group co-chair of the ECOG-ACRIN Cancer Research Group and chair of the Radiology Department of the University of Pennsylvania. "I congratulate the NLST team on its ongoing effort to continue to mine information from the NLST trial to help guide patient, clinician and health care policy decisions."

About ECOG-ACRIN
The ECOG-ACRIN Cancer Research Group designs and conducts biomarker-driven cancer research involving adults who have or are at risk of developing cancer. ECOG-ACRIN was formed in May 2012 by the merger of the Eastern Cooperative Oncology Group (ECOG) and the oncology program of the American College of Radiology Imaging Network (ACRIN). ECOG-ACRIN has integrated therapeutic and diagnostic imaging-based research disciplines with the latest bioinformatics technologies into a single scientific organization. With its capacity to explore integral biomarkers, including imaging markers of response and prognosis, ECOG-ACRIN is poised to achieve patient-centered research breakthroughs across the cancer care continuum, from prevention and screening through the treatment of metastatic disease. www.ecog-acrin.org.

About ACRIN
ACRIN engages a global network of investigators dedicated to advancing the practice of medical imaging through the conduct of multicenter clinical trials that deliver critical information to improve patient care. The network's imaging research encompasses a broad range of disease types including cardiovascular, neurological, and oncologic and imaging modalities including advanced MRI and CT, PET with novel radiotracers and new technology such as tomosynthesis. ACRIN is administered by the American College of Radiology and is headquartered at the ACR Clinical Research Center in Philadelphia, PA. The ACRIN Biostatistics Center is located at Brown University in Providence, RI.

Source: Newswise
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
International Day of Persons with Disabilities 2021 - Fighting for Rights in the Post-COVID Era
Effect of Blood Group Type on COVID-19 Risk and Severity
Woman with Rare Spinal Cord Defect from Birth Sues Doctor
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Lung Cancer Cancer Pneumoconiosis Silicosis Common Lifestyle Habits that Cause Diseases Health Benefits of Dandelion Plant Lobectomy Immune Checkpoint Inhibitors for Cancer Treatment Non-Communicable Diseases 
Recommended Reading
Common Lifestyle Habits that Cause Diseases
Cigarette smoking, unhealthy diets, overuse of alcohol, and physical inactivity are some of the most...
Health Benefits of Dandelion Plant
What is dandelion? Dandelion greens are nutrition powerhouses with a wide range of health benefits. ...
Immune Checkpoint Inhibitors for Cancer Treatment
Immune checkpoint inhibitors are promising drugs to treat a variety of cancers and the FDA has appro...
Lung Cancer
Lung cancer is a malignant tumor in the lung tissues. Smoking is the main cause of lung cancer with ...
Non-Communicable Diseases
Non-Communicable Diseases (NCDs) are a group of chronic non-infectious diseases which include Cardio...
Pneumoconiosis
Pneumoconiosis is a group of lung diseases caused by inhaled dust particles. It causes inflammation ...
Silicosis
Silicosis is a lung disease caused by inhalation of crystalline free silica dust. It is characterise...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use